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Abstract
Due to extremely poor prognosis, pancreatic cancer 
(PDAC) represents the fourth leading cause of cancer-
related death in Western countries. For more than a 
decade, gemcitabine (Gem) has been the mainstay 
of first-line PDAC treatment. Many efforts aimed 
at improving single-agent Gem efficacy by either 
combining it with a second cytotoxic/molecularly 
targeted agent or pharmacokinetic modulation provided 
disappointing results. Recently, the field of systemic 
therapy of advanced PDAC is finally moving forward. 
Polychemotherapy has shown promise over single-agent 
Gem: regimens like PEFG-PEXG-PDXG and GTX provide 
significant potential advantages in terms of survival 
and/or disease control, although sometimes at the cost 
of poor tolerability. The PRODIGE 4/ACCORD 11 was 
the first phase Ⅲ trial to provide unequivocal benefit 
using the polychemotherapy regimen FOLFIRINOX; 
however the less favorable safety profile and the 
characteristics of the enrolled population, restrict the 
use of FOLFIRINOX to young and fit PDAC patients. The 
nanoparticle albumin-bound paclitaxel (nab -Paclitaxel) 
formulation was developed to overcome resistance due 
to the desmoplastic stroma surrounding pancreatic 
cancer cells. Regardless of whether or not this is its 
main mechanisms of action, the combination of nab -
Paclitaxel plus Gem showed a statistically and clinically 
significant survival advantage over single agent Gem 
and significantly improved all the secondary endpoints. 
Furthermore, recent findings on maintenance therapy 
are opening up potential new avenues in the treatment 
of advanced PDAC, particularly in a new era in which 
highly effective first-line regimens allow patients 
to experience prolonged disease control. Here, we 
provide an overview of recent advances in the systemic 
treatment of advanced PDAC, mostly focusing on recent 
findings that have set new standards in metastatic 
disease. Potential avenues for further development in 
the metastatic setting and current efforts to integrate 
new effective chemotherapy regimens in earlier stages 
of disease (neoadjuvant, adjuvant, and multimodal 
approaches in both resectable and unresectable 
patients) are also briefly discussed.
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Core tip: In this paper, we provide an overview on the 
latest progress in the systemic treatment of advanced 
pancreatic cancer, mostly focusing on recent findings 
that have set new standards in metastatic disease. 
Potential avenues for further development in the 
metastatic setting and current efforts to integrate new 
effective chemotherapy regimens in earlier stages 
of disease (neoadjuvant, adjuvant, and multimodal 
approaches in both resectable and unresectable 
patients) are also briefly discussed.
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INTRODUCTION
Pancreatic cancer ranks as the fourth leading cause 
of cancer-related deaths in the United States and in 
most Western countries[1]. With a 5-year survival rate 
of 6% and mortality closely approaching incidence 
(approximately 46000 new cases and 39000 deaths 
estimated in the United States in 2014), pancreatic 
adenocarcinoma (PDAC) remains arguably the most 
aggressive[1,2] and resistant among solid tumors, 
to either classic chemotherapeutics[3] or targeted 
agents[4].
Besides the dismal prognosis, PDAC patients are 
usually affected by a complex association of symptoms 
(obstructive jaundice, pain, and weight loss, etc.) that 
require prompt and frequent palliative measures in 
order to improve patient performance status (PS) and 
quality of life (QoL), regardless of the specific oncologic 
treatment adopted[5,6]. 
Before the advent of gemcitabine (Gem), fluorouracil 
(5-FU), in different doses, schedules, and combination 
regimens, has been considered the cornerstone in the 
palliative treatment of advanced PDAC. A Cochrane 
systematic review[7] demonstrated that 5-FU-based 
chemotherapy significantly prolongs 6- and 12-mo 
survival [odds ratio (OR) = 0.37, 95% confidence 
interval (CI): 0.25-0.57, P value < 0.00001 for the 
12-mo comparison], compared to best supportive 
care, providing significant clinical benefits in at least 
one study[8]. However, no significant difference was 
found in one-year mortality for 5-FU alone vs 5-FU 
combinations (OR = 0.90, 95%CI: 0.62 -1.30)[7].
PAST: GEM AS THE CORNERSTONE OF 
SYSTEMIC THERAPY
Since the first demonstration of clinical benefit in 
1997, Gem has been the cornerstone of first-line 
PDAC treatment. In a phase Ⅲ study, Burris et al[9] 
randomized 126 locally advanced or metastatic PDAC 
patients to receive Gem 1000 mg/m2 (once weekly for 
7 wk followed by a week of rest and then once weekly 
for 3 out of 4 wk) or 5-FU 600 mg/m2 (once weekly). 
Patients had to be symptomatic at study entry (70% 
of the patients had a Karnofsky PS - KPS < 80%). 
Indeed, the primary study endpoint was clinical 
benefit response (CBR), a composite assessment of 
pain, analgesic consumption, KPS, and weight[10,11]. 
Gem demonstrated to be superior to 5-FU in terms 
of CBR (23.8% vs 4.8%, P = 0.0022), and relatively, 
unexpectedly in the secondary endpoint of overall 
survival (OS) (5.65 mo vs 4.41 mo, P = 0.0025). In 
addition, the 6-, 9-, and 12-mo survival rates were 
higher with Gem (46%, 24%, and 18%, respectively) 
than with 5-FU (31%, 6%, and 2%, respectively)[9], 
although the real impact of Gem, as compared to 5-FU, 
on OS has been questioned by subsequent meta-
analyses[12].
One approach aimed at improving Gem activity 
has been pharmacokinetic modulation, achieved by 
prolonging the infusion time[13-16]. This approach is 
justified by the observation that deoxycytidine kinase, 
the enzyme that catalyzes the conversion of Gem to 
its active triphosphate metabolite, is rapidly saturated 
at plasma concentrations achieved with the standard 
30-min infusion. Indeed, Gem doses of 300-350 
mg/m2 infused over 30 min have reportedly failed 
to result in increased intracellular accumulation of 
Gem triphosphate in peripheral blood mononuclear 
cells[17-19]. Conversely, infusion of the same Gem doses 
over a prolonged period at a constant dose rate of 10 
mg/m2 per minute would avoid enzyme saturation 
and permit greater intracellular accumulation, possibly 
increasing Gem antitumor activity. Fixed dose-rate 
(FDR) Gem infusion has proven feasible, well tolerated 
(even in patients with impaired liver function[20]), and 
has shown promising clinical activity[15,21,22]. Although, 
FDR-Gem failed to significantly extend survival over 
standard 30-min infusion in a randomized phase Ⅲ 
trial, pharmacokinetic Gem modulation did show a 
trend towards increased clinical activity and proved 
equivalent by adding a second chemotherapy drug 
(oxaliplatin) to a Gem backbone. However, FDR-Gem 
was administered at a higher (1500 mg/m2) weekly 
dose, as compared to the standard 30-min infusion 
(administered at 1000 mg/m2)[23].
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Until recently, efforts to improve on single-agent 
Gem efficacy by combining it with either a second 
cytotoxic drug or a molecularly targeted agent have 
failed[24,25]. The addition of erlotinib, an oral epidermal 
growth factor receptor tyrosine kinase inhibitor, to Gem 
has produced a clinically negligible, albeit statistically 
significant, improvement in OS in advanced, inoperable 
PDAC[26]. Even though, the combination of Gem and 
erlotinib is not widely employed, particularly in Europe, 
currently available evidence suggests that PDAC 
patients who develop skin toxicity during treatment 
may derive substantial benefit from this approach[27-29].
The addition of oxaliplatin to Gem in the study 
by Louvet et al[30] improved response rate (ORR), 
progression-free survival (PFS) and CBR over single 
agent Gem, but no statically significant difference in 
OS was observed (9.0 mo vs 7.1 mo, respectively, 
P = 0.13). Similar results were shown in a second 
study on the combination of Gem/oxaliplatin, in which 
combination therapy was actually therapeutically 
equivalent to FDR-Gem alone[23]. Similarly, cisplatin 
plus Gem showed no statistically significant benefit 
in survival, with comparable tumor responses 
and PFS[31,32]. The Gem/capecitabine combination 
demonstrated a significant improvement in ORR 
(19.1% vs 12.4%, P = 0.034) and PFS [hazard ratio 
(HR) = 0.78, 95%CI: 0.66-0.93; P = 0.004)] but 
failed to increase OS (HR = 0.86, 95%CI: 0.72-1.02; 
P = 0.08)[33].
The overall negative results with Gem-based 
combinations have generally been attributed to a 
lack of statistical power to detect small differences in 
survival, thus prompting for cumulative analyses that 
could detect small survival differences with adequate 
statistical power. Several meta-analyses have been 
conducted with the aim of assessing the potential 
of Gem-based chemotherapy doublets to increase 
survival in advanced PDAC.
Our group conducted a literature-based meta-
analysis on 6296 patients enrolled in 20 randomized 
clinical trials comparing the single agent Gem vs Gem-
based combinations[24]. No survival benefits were 
observed with combination therapies [relative risk 
(RR) = 0.93, 95%CI: 0.84-1.03; P = 0.17). However, 
a statistically significant, albeit minimal, advantage for 
Gem-based combinations was found for PFS (RR = 
0.91, 95%CI: 0.84-0.98; P = 0.015) and ORR (RR = 
1.57, 95%CI: 1.31-1.86; P < 0.0001): this translates 
into a number of patients needed to treat for a single 
patient to benefit (NNT) of 39 patients for PFS (with a 
2.6% absolute benefit) and 33 patients for ORR. None 
of the 4 different combination groups (Gem plus a 
platinum salt, Gem plus a fluoropyrimidine, Gem plus 
other classical cytotoxic agents, and Gem plus targeted 
drugs) demonstrated an OS benefit over single-
agent Gem, while significant advantages in PFS (RR = 
0.67, 95%CI: 0.53-0.83; P = 0.0004) and ORR were 
obtained for platinum-containing combinations[24].
Several other meta-analyses have been conducted, 
exploring whether adding a second drug to Gem would 
impact on survival of advanced PDAC patients. Sultana 
et al[12] conducted a meta-analysis on 19 studies, 
involving 4697 patients, and found a statistically 
significant, but clinically negligible, OS benefit for Gem-
based combinations (HR= 0.91, 95%CI: 0.85-0.97; 
P = 0.004), particularly when Gem was combined 
with platinum salts. Heinemann et al[32] analyzed 15 
randomized trials involving 4465 patients. Overall, they 
demonstrated a small, albeit statistically significant, 
survival advantage for Gem-based combinations, 
as compared to single-agent Gem (HR = 0.91, P 
= 0.004). The combined analysis of 5 randomized 
trials showed a significant prolongation in OS (HR = 
0.85, P = 0.010) and a significant benefit in PFS and 
ORR for the combination of Gem with platinum salt. 
Meta-analytic results from 6 studies demonstrated a 
significant, albeit modest, improvement in survival 
(HR = 0.90, P = 0.03) for Gem/fluoropyrimidine 
combination, more pronounced when the association 
with capecitabine in 3 trials was considered (HR = 
0.83, P = 0.01). In a subgroup analysis conducted 
on 1682 patients (38% of the overall population) for 
whom PS data were available, OS benefit for Gem-
based combinations seemed to be confined to patients 
with good PS (HR = 0.76, P < 0.001)[34]. All these 
data are consistent with previous meta-analytic results 
showing no difference in 1-year mortality rate between 
Gem-combination and single agent Gem (OR = 0.88, 
95%CI: 0.74-1.05) and a better 6-mo mortality rate 
for the subgroup of platinum/Gem schedules (OR = 
0.59, 95%CI: 0.43-0.81; P = 0.001)[7]. Xie et al[35] 
evaluated 18 randomized trials involving 4237 patients 
and showed a reduction of 9% in the risk of death with 
Gem-based doublets at 6 mo (RR = 0.91, 95%CI: 
0.85-0.97; P = 0.005) and of 4% at 1 year (RR = 0.96, 
95%CI: 0.93-0.99; P = 0.02); Gem/capecitabine and 
Gem/oxaliplatin combinations significantly reduced 
the risk of death by 15% (RR = 0.85, 95%CI: 
0.73-0.99; P = 0.04) and 20% (RR = 0.80, 95%CI: 
0.70-0.91; P = 0.001), respectively. No survival 
benefit was shown for Gem-based combinations in 
the good PS group of patients and an increased risk 
of death was demonstrated for patients with poor PS. 
A further meta-analysis on thirty-five trials and a total 
of 9979 patients demonstrated that the Gem-based 
combination treatments achieved a significant benefit 
over single agent Gem (OS: OR = 1.15, P = 0.011; 
PFS: OR = 1.27, P < 0.001; ORR: OR = 1.58, P < 
0.001). Improvement in terms of survival and ORR 
were especially evident when Gem was combined with 
fluoropyrimidines (OS: OR = 1.33, P = 0.007; PFS: 
OR = 1.53, P < 0.001; ORR: OR = 1.47, P = 0.03). 
Similar results were obtained for the combination with 
oxaliplatin (OS: OR = 1.33, P = 0.019; PFS: OR = 1.38, 
P = 0.011)[36]. A more recent meta-analysis provided a 
statistically significant, even though marginal, survival 
4790 April 28, 2015|Volume 21|Issue 16|WJG|www.wjgnet.com
Vaccaro V et al . Systemic therapy for advanced PDAC
in very aggressive diseases, such as advanced PDAC, 
QoL is influenced more by disease-related symptoms 
than treatment-related toxicity. One of the limits of 
Conroy’s trial is that enrollment was restricted to 
patients younger than 76 years, with an Eastern 
Cooperative Oncology Group (ECOG) PS score of 0 or 
1 and a bilirubin level ≤ 1.5 times the upper normal 
limit; thus, the proportion of patients carrying a biliary 
stent was relatively low (14.3%). On these bases, the 
FOLFIRINOX regimen is currently recommended as 
a first-line treatment option for young and fit PDAC 
patients, with good hepatobiliary function, and dose/
schedule modifications are applied by many groups, in 
order to avoid excessive toxicity[41-48].
Before the advent of FOLFIRINOX, other groups 
had shown potential advantages for polychemotherapy 
over single-agent Gem in advanced PDAC. In 2005, 
Reni et al[49] performed a randomized phase Ⅲ study 
in locally advanced or metastatic pancreatic cancer 
with the PEFG regimen, consisting of cisplatin 40 mg/
m2 and epirubicin 40 mg/m2 given on day 1, Gem 600 
mg/m2 administered on days 1 and 8 and 5-fluorouracil 
200 mg/m2 per day as continuous infusion during the 
entire duration of chemotherapy treatment, with cycles 
repeated every 28 d. Primary endpoint was 4-mo PFS 
improvement with the four-drug combination over 
single-agent Gem. A previous phase Ⅱ study on the 
same regimen showed interesting ORR results (55% 
in the metastatic population), survival (median time 
to tumor progression 7 mo and median OS 9.5 mo), 
and safety profile[49]. In the phase Ⅲ trial the primary 
endpoint was met with a total of 99 patients enrolled 
(affected by either metastatic or locally advanced 
disease) and a median follow-up of 33.5 mo, more 
than 30% absolute difference in 4-mo progression-
free survival was observed (4-mo PFS: 60%, 95%CI: 
46-72, vs 28%, 95%CI: 17-42; HR = 0.46, 95%CI: 
0.26-0.79; P = 0.001). Median PFS was 5.4 mo 
(95%CI: 2.0-9.6 mo) for the combination regimen 
vs 3.3 mo (95%CI: 2.2-5.3) for Gem (HR = 0.51, 
95%CI: 0.33-0.78; P = 0.0033); the HR for death 
in the PEFG group compared with the Gem group 
was 0.65 (95%CI: 0.43-0.99; P = 0.047). Disease 
response was reported in 38.5% (95%CI: 25.3-51.7) 
in the combination group compared to 8.5% (95%CI: 
0.5-16.5) in the monochemotherapy group (OR = 6.60, 
95%CI: 2.11-20.60; P = 0.0008). PEFG was quite 
well tolerated, although more patients experienced 
grade 3-4 neutropenia and thrombocytopenia in the 
PEFG group (P < 0.0001)[50]. The small sample size 
and the choice of PFS as the primary endpoint may 
have constituted a weakness of the study, making 
the results difficult to generalize, leading to a general 
reluctance to widely adopt such a regimen as a possible 
standard in advanced PDAC[51]. Other concerns include 
the toxicity profile and the potential impairment in QoL 
in an already usually highly symptomatic population 
of patients[51]. A simplified schedule characterized 
by a better toxicity profile, more suitable for routine 
improvement over single agent Gem (pooled HR = 
0.93; 95%CI: 0.89-0.97; P = 0.001). As observed by 
the authors, such slight improvements were obtained 
at the price of a significantly greater incidence of 
toxic effects, notably diarrhea, nausea, neutropenia 
and thrombocytopenia[37]. Although slight differences 
were obtained in the results, overall all of these meta-
analyses ultimately convey the very same message, 
that is summarized in the results of a recent pooled 
analysis, performed by our group: when the results of 
7 randomized trials comparing Gem-monotherapy with 
the three most popular combination regimens (Gem/
cisplatin, Gem/capecitabine and Gem/oxaliplatin) were 
pooled together, a clinically negligible, albeit statistically 
significant, absolute survival benefit (2%-3% at 1 
year) was observed, ruling out the possibility that 
Gem-based combination regimens could improve 
1-year survival by more than 5%[38]. Thus, the routine 
use of Gem-based doublets with either platinum salts 
or fluoropyrimidines in metastatic PDAC does not seem 
to be supported by available evidence.
PRESENT: FOLFIRINOX AND OTHER 
POLYCHEMOTHERAPY APPROACHES
The multicentre, randomized, phase Ⅱ-Ⅲ trial 
PRODIGE 4/ACCORD 11, comparing single-agent Gem 
with the polychemotherapy regimen FOLFIRINOX in 
patients with metastatic PDAC was published in 2011. 
Three hundred forty-two patients were randomly 
assigned to receive standard Gem 1000 mg/m2 or 
FOLFIRINOX (oxaliplatin 85 mg/m2, leucovorin 400 
mg/m2, irinotecan 180 mg/m2, 5-FU 400 mg/m2 
administered by intravenous bolus, followed by a 
continuous intravenous infusion of 2400 mg/m2 over 
a 46-h period), in cycles repeated every 2 wk. With a 
median follow-up of 26.6 mo, median OS was 11.1 mo 
(95%CI: 9.0-13.1) in the FOLFIRINOX group and 6.8 
mo (95%CI: 5.5-7.6) in the Gem group (HR = 0.57; 
95%CI: 0.45-0.73; P < 0.001); 1-year survival rate 
was 48.4% in the FOLFIRINOX group, as compared 
with 20.6% in the Gem group; HR for death remained 
significant when adjusted for independent adverse 
prognostic factors. A statistically significant difference 
was observed also for PFS (6.4 mo vs 3.3 mo, HR = 
0.47; 95%CI: 0.37-0.59; P < 0.001). An impressive 
ORR of 31.8% in the FOLFIRINOX group was reported, 
as compared to 11.3% in the Gem group. Results 
were not influenced by second-line treatments, in fact 
approximately 45% of patients in both groups received 
second-line therapy. As expected, FOLFIRINOX’s 
safety profile was less favorable, with a significantly 
higher incidence of grade 3 or 4 neutropenia, febrile 
neutropenia, thrombocytopenia, diarrhea, and 
sensory neuropathy, as well as grade 2 alopecia[39]. 
Nevertheless, health-related QoL analysis showed that 
FOLFIRINOX significantly reduces QoL impairment, 
as compared with Gem[40], highlighting the fact that 
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clinical use, was indeed proposed by the authors[52,53]. 
Other attempts at making this regimen more easily 
manageable and even more active encompassed 
substituting the oral capecitabine for 5-FU (PEXG) 
and docetaxel for epirubicin (PDXG). The results of 
a randomized phase Ⅱ study comparing PEXG and 
PDXG confirmed a very high ORR (37% and 60%, 
respectively) and notable PFS (approximately 7.5 mo 
in both arms) and OS benefit (approximately 11 mo in 
both arms)[54].
Another multidrug regimen combining Gem, doce-
taxel, and capecitabine (GTX: capecitabine 750 mg/m2 
per day, days 1-14; Gem 750 mg/m2 over 75 min on 
days 4 and 11 and docetaxel 30 mg/m2 on days 4 and 
11; cycles repeated every 21 d) was initially tested 
retrospectively in a metastatic PDAC population of 35 
patients, with a reported ORR of 29% and disease 
stabilization in an additional 31%[55]. A subsequent 
analysis included 154 patients with locally advanced 
(73 patients; 24%) or metastatic PDAC (117 patients; 
76%) treated with the GTX regimen where the 
majority of patients had an ECOG PS of 0 (29%) or 
1 (66%) and 49% of patients had received previous 
chemotherapy treatment. Metastatic patients who 
received GTX as first-line treatment achieved a median 
survival of 11.3 mo; partial response and stable 
disease were observed in 11% and 62% of patients, 
respectively. Unfortunately, responses significantly 
correlated with toxicity, namely neutropenia, ALT 
elevation and hospitalizations: 9% of patients 
experienced grade 3-4 non-hematological toxicity and 
41% experienced hematological toxicity (grade 3-4 
anemia, neutropenia and thrombocytopenia in 12%, 
34% and 13% of patients, respectively)[56].
PRESENT: GEM/NAB-PACLITAXEL
Nab-Paclitaxel is a nanoparticle albumin-bound 
(nab) paclitaxel characterized by a formulation of 
nanoparticle colloidal suspension, with an average size 
of 130 nm, prepared with human serum albumin. This 
formulation without solvents confers more favorable 
pharmacologic characteristics that allow the delivery 
of a higher dose of paclitaxel than Cremophor-
paclitaxel, significantly lowering the risk of infusion 
hypersensitivity reactions and neutropenia and a faster 
recovery of peripheral neuropathy upon stopping the 
treatment[57]. Nab-Paclitaxel uptake into cells may 
be dependent on SPARC (secreted protein acidic and 
rich in cysteine) expression. SPARC is an albumin-
binding protein that interacts with an extracellular 
matrix, influencing cell migration, proliferation, 
angiogenesis (especially during wound healing), 
matrix cell adhesion, and tissue remodeling. Pancreatic 
cancer is characterized by malignant epithelial cells 
surrounded by a rich stromal reaction, composed of 
extracellular matrix proteins (collagen, hyaluronic 
acid, SPARC) and cellular elements cancer-associated 
fibroblast, endothelial, immune, and inflammatory 
cells[58,59]. Analysis of pancreatic cancer tissue samples 
showed that SPARC is overexpressed[60] preferentially 
by stromal fibroblasts and epigenetically silenced 
in pancreatic cancer cells[61]. SPARC expression in 
peritumoral fibroblasts is a strong marker of poor 
prognosis in patients with resectable pancreatic 
adenocarcinoma, independent of common clinical 
parameters including tumor size, margin status, and 
lymph node metastasis[62-64]. As pancreatic cancer 
stroma may contribute to poor vascularisation and high 
intratumoural pressure, thereby causing decreased 
drug diffusion[65], SPARC represents an interesting 
stromal target[63] and the binding between SPARC and 
albumin may facilitate the tumor delivery of albumin-
bound therapeutic agents[58]. Indeed, preclinical 
studies on PDAC stroma targeting strategies showed 
promising results and achieved decrease intratumor 
interstitial pressure, normalized vascularisation, and 
improved drug delivery[66-68].
This stimulated researchers’ interest in testing nab-
Paclitaxel in PDAC. A phase Ⅰ/Ⅱ study was conducted 
in metastatic PDAC patients that received Gem (1000 
mg/m2) with nab-Paclitaxel (100, 125, or 150 mg/m2) 
on days 1, 8, and 15, every 28 d. In the 44 patients 
treated at the MTD of 125 mg/m2 median PFS was 7.9 
mo (95%CI: 5.8-1.0 mo), median OS was 12.2 mo 
(95%CI: 8.9-17.9 mo), and 1-year survival was 48%; 
ORR was 48%, with an overall disease control rate 
of 68%[60]. These promising results, along with the 
favorable safety profile prompted starting a phase Ⅲ 
study. 
Eight-hundred-sixty-one metastatic pancreatic 
cancer patients were enrolled in a phase Ⅲ trial and 
randomized to receive nab-Paclitaxel at a dose of 125 
mg/m2 plus Gem (1000 mg/m2) 3 wk on/1 wk off or 
single agent Gem (1000 mg/m2). OS was significantly 
improved with nab-Paclitaxel plus Gem as compared 
to Gem monotherapy (8.7 mo vs 6.6 mo, HR = 0.72, 
95%CI: 0.62-0.83; P < 0.001), as were the 1-year 
(35% vs 22%) and 2-year (10% vs 5%) survival rates. 
A significant improvement in PFS was also reported 
(5.5 mo vs 3.7 mo, HR = 0.69, 95%CI: 0.58-0.82; P 
< 0.001). The ORR was significantly higher with the 
combination treatment than with Gem (23% vs 7%; 
P < 0.001; response-rate ratio, 3.19). Disease control 
rate (DCR; confirmed response or stable disease for ≥ 
16 wk) was 48% in the nab-Paclitaxel/Gem population 
and 33% in the Gem group (ratio for disease control 
1.46; 95%CI: 1.23-1.72). The difference between 
treatment groups could not be attributed to the use of 
second-line therapy[69-71]. The most common adverse 
events related to nab-Paclitaxel/Gem combination 
were fatigue (54%), alopecia (50%), and nausea 
(49%). Grade 3 or higher adverse events were 
neutropenia (38% in the combination group vs 27% in 
the Gem group, with 3% vs 1% of febrile neutropenia, 
respectively), fatigue (17% vs 7%), and peripheral 
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neuropathy (17% vs 1%). Median time to occurrence 
of G3 peripheral neuropathy in the combination group 
was 140 d, with a median time to recovery of such 
toxicity to G1 or lower of 29 d. 44% of patients could 
then resume combined treatment and the median OS 
of patients experiencing G3 peripheral neuropathy 
was strikingly longer (14.9 mo), as compared to that 
observed in the ITT population (8.5 mo).
Stromal SPARC expression, evaluated in 36 patients 
enrolled in the phase Ⅰ/Ⅱ trial by Von Hoff et al[61] was 
demonstrated to be a predictor factor for OS. Patients 
with high-SPARC expression showed a prolonged OS 
compared with low-SPARC expression group (median 
OS: 17.8 mo vs 8.1 mo, respectively; P = 0.0431). 
No significant correlation with OS was reported for 
the expression of SPARC in tumor cells[60]. Conversely, 
the exploratory analysis of the MPACT study on the 
prognostic significance of SPARC expression did 
not show any correlation with OS. Stromal SPARC 
was neither a prognostic factor, nor a significant, 
independent predictive factor for OS or secondary 
endpoints, such as PFS, TTF, ORR and DCR. In an 
additional analysis, tumor epithelial SPARC, baseline and 
change from baseline of plasma SPARC were similarly 
not predictive for OS. However, only 256 patients (30% 
of the ITT population) were evaluable for stromal SPARC 
expression, among the 860 patients enrolled in the 
MPACT study, and the IHC assay was different from that 
employed in the phase Ⅰ/Ⅱ trial, although it showed 
86% concordance[72]. These two aspects, together 
with differences in patient characteristics and tissue of 
origin, may explain to some extent the failure of such 
exploratory analysis to highlight a significant predictive 
value of SPARC expression in this setting. However, 
a closer look at survival curves according to SPARC 
expression does reveal differences that may have 
potential biological and clinical meaning, although they 
do not reach statistical significance, thus supporting 
the continued exploration of a potential role of SPARC 
expression in regulating sensitivity to nab-Paclitaxel/
Gem combinations. 
FUTURE: IS THERE A RATIONALE FOR 
MAINTENANCE THERAPY?
Maintenance therapy refers to systemic therapy 
given to cancer patients who have achieved an 
objective response or disease stabilization after first 
line treatment, with the aim to extend responses 
or delay recurrence, eventually prolonging OS. The 
maintenance approach is largely used for hematologic 
malignancies and has been recently investigated in 
solid tumors, providing conflicting results. In breast 
cancer this strategy seems to improve PFS without 
OS benefit; in colorectal cancer no evidence exists in 
favor of continuous treatment[73]. A PFS advantage 
can be obtained with maintenance paclitaxel or 
maintenance bevacizumab in ovarian cancer, while 
maintenance therapy has been approved by the 
US Food and Drug Administration for advanced 
NSCLC[74-76]. With regard to pancreatic cancer, the 
trial recently published by Reni et al[77] was the first 
to address the role of a maintenance strategy in this 
disease. They performed a multicentre phase Ⅱ study 
in which 56 metastatic PDAC patients, who were 
progression-free after 6 mo from the start of first line 
chemotherapy, were randomized to receive sunitinib 
37.5 mg/d continuously or observation only, with the 
primary endpoint of a 20% improvement in 6-mo PFS 
(PFS-6). The study met its primary endpoint: PFS-6 
was 3.6% (95%CI: 0%-10.6%) in the observation 
group and 22.2% (95%CI: 6.2%-38.2%) in patients 
receiving sunitinib. Median PFS were 2.0 and 3.2 mo, 
respectively (P < 0.01, HR = 0.51, 95%CI: 0.29-0.89). 
Although differences in OS did not reach statistical 
significance (HR = 0.71, 95%CI: 0.40-1.26; P = 0.11), 
the proportion of patients who were alive at two years 
was tripled in the sunitinib maintenance arm (22.9% 
vs 7.1%), as compared with the observation arm. Most 
common grade 3-4 adverse events in the experimental 
arm were: thrombocytopenia, neutropenia and hand-
foot syndrome (12%) and diarrhea (8%). Although 
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Table 1  Selected adjuvant or “strategy” (neoadjuvant vs  adjuvant) clinical trials employing contemporary treatment regimens for 
resectable pancreatic adenocarcinoma
Study ID1 Design Phase Estimated accrual Status
NCT00882310 Adjuvant Gem, Taxotere, and Xeloda Ⅱ 32 Active, not recruiting
NCT00960284 Post-operative Gemcitabine vs PEFG Followed by Chemoradiation Ⅱ/Ⅲ 102 Completed
NCT01150630 Adjuvant Gem vs Adjuvant PEXG vs Neoadjuvant/Adjuvant PEXG Ⅱ/Ⅲ 370 Recruiting
NCT01526135 Adjuvant Gem vs modified FOLFIRINOX2 Ⅲ 490 Recruiting
NCT01660711 Neoadjuvant/Adjuvant modified FOLFIRINOX3 Ⅱ 21 Recruiting
NCT01845805 Adjuvant nab-Paclitaxel/Gem/Azacitidine Ⅱ 80 Recruiting
NCT01964430 Adjuvant Gem vs nab-Paclitaxel/Gem (APACT) Ⅲ 800 Recruiting
NCT02023021 Adjuvant nab-Paclitaxel/Gem Ⅱ 80 Recruiting
NCT02047474 Neoadjuvant/Adjuvant modified FOLFIRINOX4 Ⅱ 46 Recruiting
NCT02047513 Adjuvant only vs Neoadjuvant/Adjuvant nab-Paclitaxel/Gem (NEONAX) RⅡ5 166 Not yet recruiting
NCT02172976 Adjuvant Gemcitabine vs Neoadjuvant/Adjuvant FOLFIRINOX Ⅱ/Ⅲ 126 Not yet recruiting
1ClinicalTrials.gov Identifier; 2Oxaliplatin 85 mg/m2, Irinotecan 165 mg/m2, Leucovorin 400 mg/m2, fluorouracil (5-FU) 2400 mg/m2 c.i.v.i. over 48 h (no 
5-FU bolus); 3Oxaliplatin 85 mg/m2, Irinotecan 180 mg/m2, Leucovorin 400 mg/m2, 5-FU 2400 mg/m2 c.i.v.i. over 48 h (no 5-FU bolus); 4Dose/schedule 
modifications not specified; 5Randomized phase Ⅱ.
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Table 2  Selected ongoing studies of contemporary “nanoparticle albumin-paclitaxel-based” systemic therapy in borderline 
resectable, locally advanced and metastatic pancreatic cancer
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Title (Study ID1) Phase Stage Status
Randomized Phase Ⅱ Trial of Pre-Operative Gemcitabine and nab-Paclitaxel With or With Out 
Hydroxychloroquine (NCT01978184)
Phase 2 Potentially 
resectable 
Recruiting
Phase 1/2 Safety and Feasibility of Gemcitabine and nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant 




A Pilot Phase Ⅱ Multi Center Study of Gemcitabine and nab-Paclitaxel (Abraxane) as Preoperative Therapy for 
Potentially Operable Pancreatic Cancer (NCT01298011)
Phase 2 Resectable Active, not 
recruiting
Phase Ⅱ Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable 
Pancreatic Cancer (NCT02243007)
Phase 2 Resectable Not yet 
recruiting
Phase Ⅱ Neoadjuvant Chemotheraphy (Gemcitabine and nab-Paclitaxel vs mFOLFIRINOX) and Sterotatic Body 
Radiation Therapy for Borderline Resectable Pancreatic Cancer (NCT02241551)
Phase 2 BR Not yet 
recruiting
Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced and 
Borderline Resectable Pancreatic Cancer (NCT02283372)
Phase 1 BR or LA Not yet 
recruiting
A Phase Ⅰ Dual Dose Escalation Study of Radiation and nab-Paclitaxel in Patients With Unresectable and 
Borderline Resectable Pancreatic Cancer (NCT02207465)
Phase 1 BR or LA 
unresectable 
Recruiting
A Phase 2 Trial of Gemcitabine Plus nab-Paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in 
Locally Advanced, Unresectable Pancreatic Cancer (NCT02210559)
Phase 2 LA, 
unresectable 
Recruiting
A Phase Ⅰ Study of Chemoradiotherapy Using Gemcitabine Plus nab-Paclitaxel for Unresectable Locally Advanced 
Pancreatic Adenocarcinoma (NCT02272738)
Phase 1 LA, 
unresectable 
Recruiting
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Investigate the Safety and Pharmacokinetics of Nab® 
- Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic 
Hyperbilirubenemia Secondary to Bile Duct Obstruction (NCT02267707)





Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine 
and nab-Paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic 
Adenocarcinoma (NCT01715142)
Phase 0 Stage I-Ⅱ-Ⅲ-Ⅳ Not yet 
recruiting
A Phase Ⅱ Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine 
Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane 
Pancreas) Trial (NCT02043730)
Phase 2 Stage Ⅲ Active, not 
recruiting
A Multicenter Phase Ⅰ/Ⅱ Randomized Phase Ⅱ Study of Gemcitabine and nab-Paclitaxel With or Without NPC-1C 




A Phase IB Study of Erlotinib in Combination With Gemcitabine and nab-Paclitaxel in Patients With Previously 
Untreated Advanced Pancreatic Cancer (NCT01010945)
Phase 1 Stage Ⅲ-Ⅳ Completed
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent and in 
Combination With Gemcitabine and nab-Paclitaxel in Patients With Advanced Solid Tumors (NCT01804530)
Phase 1 Stage Ⅲ-Ⅳ Recruiting
An Open-Label, Phase Ⅰ Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel 
in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma 
(NCT02047500)
Phase 1 Stage Ⅲ-Ⅳ Recruiting
Phase Ⅱ Study Evaluating Bi-weekly Dosing of Gemcitabine Plus nab-Paclitaxel in the Treatment of Surgically 
Unresectable/Metastatic Pancreatic Cancer (NCT01851174)
Phase 2 Stage Ⅲ-Ⅳ Recruiting
Phase 1B Trial of ADI-PEG 20 Plus nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer 
(NCT02101580)
Phase 1 Stage Ⅲ-Ⅳ Not yet 
recruiting
Phase Ⅱ Trial of Abraxane® in the Treatment of Patients With Pancreatic Cancer Who Have Failed First-Line 
Treatment With Gemcitabine-Based Therapy (NCT00691054)
Phase 2 Stage Ⅲ-Ⅳ Completed
A Phase Ⅰ/Ⅱ/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to 




BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic 
Cancer (NCT02155088)
Phase 1 Stage Ⅲ-Ⅳ Recruiting
A Phase Ⅰ and Randomized, Double-Blinded Phase Ⅱ Study of nab-paclitaxel/Gemcitabine Plus AZD1775 or 




A Phase Ib Study of Dovitinib in Combination With Gemcitabine and nab-Paclitaxel in Patients With Advanced 
Solid Tumors and Pancreatic Cancer (NCT02048943)




Phase I-Ⅱ Trial of Gemcitabine Plus nab-Paclitaxel (GemBrax) Followed by Folfirinox as First Line Treatment of 




A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With nab-Paclitaxel and 
Gemcitabine in Patients With Previously Untreated Stage Ⅳ Pancreatic Cancer (NCT02005315)
Phase 1 Stage Ⅳ Recruiting
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With nab-Paclitaxel and Gemcitabine in Patients 
With Previously Untreated Stage Ⅳ Pancreatic Cancer (NCT02050178)
Phase 1 Stage Ⅳ Recruiting
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) 
Combined With nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With 
Stage Ⅳ Previously Untreated Pancreatic Cancer (NCT01839487)
Phase 2 Stage Ⅳ Recruiting
A Phase Ⅰ/Ⅱ Study of Indoximod in Combination With Gemcitabine and nab-Paclitaxel in Patients With Metastatic 
Adenocarcinoma of the Pancreas (NCT02077881)
Phase 1
Phase 2
Stage Ⅳ Not yet 
recruiting
A Phase 1b/2 Study of OMP-59R5 in Combination With nab-Paclitaxel and Gemcitabine in Subjects With 




Phase Ⅰ Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus nab-Paclitaxel in Patients With Metastatic 
Pancreatic Cancer (NCT01934634)
Phase 1 Stage Ⅳ Recruiting
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the study has obvious limitations (small sample size 
above all), it does provide a proof of the principle that 
switch maintenance in appropriately selected patients 
may indeed be beneficial in advanced PDAC; this 
becomes all the more relevant now that the proportion 
of advanced PDAC patients who reach the 6-mo 
landmark without experiencing progression of their 
disease is up to approximately 50% with contemporary 
first-line chemotherapy (such as FOLFIRINOX or nab-
Paclitaxel/Gem). Such provocative findings open up 
an entirely new field in the treatment of PDAC, which 
clearly deserves further investigation.
WHERE DO WE GO FROM HERE?
Despite twenty years of well-deserved therapeutic 
nihilism[24,78,79], the field of systemic therapy for 
advanced/metastatic pancreatic cancer is finally 
moving forward: in only three years the median and 
1-year OS have almost doubled from the 6 mo and 
20% of the Gem era to the 9-11 mo and 35%-48% 
achieved with nab-Paclitaxel/Gem and FOLFIRINOX. 
Such evidence clearly sets new standard(s) of systemic 
therapy in metastatic pancreatic cancer, so that the use 
of Gem monotherapy appears nowadays justified only 
in a minority of patients, characterized by suboptimal 
PS (KPS < 70%), advanced age, and/or significant 
comorbidities. These results also substantially raise the 
bar for the design of present and future clinical trials, 
where the use of Gem monotherapy as the standard 
comparator arm is no longer acceptable, except, 
perhaps, in specific subpopulations of unfit patients. 
The first burning question is: how will such advances 
in systemic therapy impact on outcomes in earlier 
stages of disease [locally advanced (LAPC), borderline 
resectable (BRPC), and frankly resectable disease], 
where there is, theoretically, much more to be gained 
and patients may be rendered NED and potentially 
cured? FOLFIRINOX is being actively pursued as a 
neoadjuvant/induction chemotherapy regimen in the 
multimodal management of LAPC and BRPC[45,46,80-83], 
most often with dose modifications aimed at improving 
tolerability and reducing the risk of serious toxicity: 
with ORR ranging from 27% to 50% and resectability 
rates of 12%-51%, such approach appears promising, 
although its ultimate impact on survival endpoints 
(median PFS ranging from 8 to 13 mo and median 
OS approximately 22 mo), as compared with more 
traditional regimens, will need to be judged on more 
congruous numbers of patients with adequate follow 
up. The combination of nab-Paclitaxel and Gem is 
also an attractive neoadjuvant treatment strategy for 
LAPC and BRPC. Although, currently available data 
in this setting are still anecdotal (case reports and 
preliminary reports of small case series)[84-88], such 
combination is extremely interesting, particularly 
because of the peculiar mechanism of action, which 
may encompass stromal depletion, arguably much 
more relevant in the primary pancreatic tumor than 
in metastatic lesions[58]. Even more importantly, both 
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A Phase Ⅰ Study of nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With 
Previously Untreated, Metastatic Pancreatic Adenocarcinoma (NCT01161186)
Phase 1 Stage Ⅳ Completed
A Phase 1b/2 Pilot Trial of nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously 




A Phase Ⅰ/Ⅱ, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With nab-




A Phase 2, Randomized, Double-blind Study of Gemcitabine And nab-Paclitaxel Combined With Momelotinib in 
Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, 
Lead-in Phase (NCT02101021)
Phase 2 Stage Ⅳ Not yet 
recruiting
Phase 1/2 Study Of PF-03084014 In Combination With Gemcitabine And nab-Paclitaxel In Patients With Previously 
Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NCT02109445)
Phase 1
Phase 2
Stage Ⅳ Not yet 
recruiting
Phase Ⅰ/Ⅱ Study to Evaluate nab-Paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as 




A Randomized, Double-Blinded, Placebo-Controlled Phase Ⅱ Trial Of Gemcitabine Plus nab-Paclitaxel Combined 
With OGX-427 Or Placebo In Patients With Metastatic Pancreatic Cancer (The Rainier Trial) (NCT01844817)
Phase 2 Stage Ⅳ Recruiting
A Phase Ⅱ Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients With 
Metastatic Pancreatic Cancer (NCT02242409)
Phase 2 Stage Ⅳ Recruiting
Enzalutamide in Combination With Gemcitabine and nab-Paclitaxel for the Treatment of Advanced Pancreatic 
Cancer (NCT02138383)
Phase 1 Stage Ⅳ Recruiting
A Phase Ib/Ⅱ Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and nab-Paclitaxel 
in Patients With Metastatic Pancreatic Cancer (NCT02178436)
Phase 1
Phase 2
Stage Ⅳ Not yet 
recruiting
Phase Ⅱ Trial of nab-Paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer 
(NCT02124317)
Phase 2 Stage Ⅳ Recruiting
Biological Effect of nab-Paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer (NCT02174887) Phase 1 Stage Ⅳ Not yet 
recruiting
A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, 
Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal 
Adenocarcinoma (NCT02289898)
Phase 2 Stage Ⅳ Not yet 
recruiting
A Phase Ib Clinical Study of BBI608 in Combination With Gemcitabine and nab-Paclitaxel in Adult Patients With 
Metastatic Pancreatic Adenocarcinoma (NCT02231723)
Phase 1 Stage Ⅳ Recruiting
Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer (NCT02135822) Phase 2 Advanced Recruiting
1ClinicalTrials.gov Identifier. nab-Paclitaxel: Nanoparticle albumin-bound paclitaxel.
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Table 3  Selected ongoing studies of ”folfirinox-based”and other contemporary regimens in borderline resectable, locally advanced 
and metastatic pancreatic cancer
Title (Study ID1) Phase Stage Status
A Phase Ⅱ Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma 
With Tissue Collection (NCT02178709)
Phase 2 Resectable Recruiting
Phase Ⅱ Study of Preoperative FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Patients With Resectable 
Pancreatic Cancer (NCT02243007)
Phase 2 Resectable Not yet 
recruiting
Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally 
Advanced Pancreatic Adenocarcinoma Protocol (NCT01760252)
Phase 2 Resectable, 
BR and LA
Recruiting
GTX-RT in Borderline Resectable Pancreatic Cancer (NCT01754623) Phase 2 BR Active, not 
recruiting
Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study (NCT02148549) Phase 1 BR Recruiting
Phase Ⅱ Neoadjuvant Chemotheraphy (Gemcitabine and nab-Paclitaxel vs mFOLFIRINOX) and Sterotatic Body 
Radiation Therapy for Borderline Resectable Pancreatic Cancer (NCT02241551)
Phase 2 BR Not yet 
recruiting
Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced 
Pancreatic Adenocarcinoma (NCT01413022)
Phase 1 BR or LA Recruiting
Phase Ⅱ Single Arm Clinical Trial of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable 
Pancreatic Cancer (NCT01688336)
Phase 2 BR or LA 
unresectable 
Recruiting
Prospective Randomized Multicenter Phase Ⅱ Trial to Investigate Intensified Neoadjuvant Chemotherapy in 
Locally Advanced Pancreatic Cancer (NEOLAP) (NCT02125136)
Phase 2 LA Not yet 
recruiting
The Effect of FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable 
Pancreatic Cancer (BCC-RAD-13) (NCT02128100)




A Phase Ⅱ, Randomized, Open Label Study of Single Dose siG12D LODER in Combination With Chemotherapy 
in Patients With Unresectable Locally Advanced Pancreatic Cancer (NCT01676259)




A Prospective Evaluation of Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancreas 







Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan 
(FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an 
Expansion Cohort at the Recommended Phase 2 Dose (NCT01485744)








Phase Ⅱ Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation 





A Phase Ⅰ-Ⅱ Study of PAXG in Stage Ⅲ-Ⅳ Pancreatic Adenocarcinoma (NCT01730222) Phase 1-2 Stage Ⅲ-Ⅳ Recruiting
Phase Ⅱ Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer (NCT01523457) Phase 2 Stage Ⅲ-Ⅳ Recruiting
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally 
Advanced or Metastatic Pancreatic Cancer (NCT02227940)




Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF 
Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer (NCT01896869)
Phase 2 Stage Ⅳ Recruiting
A Phase Ⅱ Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic 
Cancer (NCT01488552)
Phase 1-2 Stage Ⅳ Recruiting
A Phase Ⅰ Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in 
Patients With Metastatic Pancreatic Cancer and Good Performance Status (NCT01835041)
Phase 1 Stage Ⅳ Recruiting
Phase ⅠB/Randomized Phase Ⅱ Study of Folfirinox Plus AMG-479 (Ganitumab) or Placebo in Patients With 




Phase Ⅱ Trial to Investigate the Efficacy and Safety of mFOLFIRINOX in Patients With Metastatic Pancreatic 
Cancer in China (NCT02028806)
Phase 2 Stage Ⅳ Recruiting
S1313, A Phase IB/Ⅱ Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human 
Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status 




Phase I-Ⅱ Trial of Gemcitabine Plus nab-Paclitaxel (GemBrax) Followed by Folfirinox as First Line Treatment of 




Phase Ⅱ Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer (NCT01523457) Phase 2 Stage Ⅳ Recruiting
Phase Ⅰ/Ⅱ Study to Evaluate nab-Paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as 




Phase Ⅱ Study for Inoperable Non-Metastatic Pancreatic Cancer (Stage ⅣA) With Neoadjuvant Gemzar, Taxotere 
and Xeloda (GTX), and Radiation With Gemzar (NCT00869258)
Phase 2 Stage Ⅳ Active, not 
recruiting
Phase Ⅱ Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin in Subjects With 
Metastatic Pancreatic Cancer (NCT01459614)
Phase 2 Stage Ⅳ Active, not 
recruiting
Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) 
of "FOLFIRINOX " Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yr or Older) With a Metastatic 
Pancreatic Adenocarcinoma (NCT02143219)
Phase 2 Stage Ⅳ Not yet 
recruiting
1ClinicalTrials.gov Identifier. BR: Borderline resectable; LA: Locally advanced; nab-Paclitaxel: Nanoparticle albumin-bound paclitaxel.
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strategies (aggressive polychemotherapy with PEFG- 
or FOLFIRINOX-like regimens and nab-Paclitaxel/Gem 
combinations) are being tested in the adjuvant setting 
or in “strategy studies”, comparing neoadjuvant vs 
adjuvant chemotherapy with such novel regimens, in an 
attempt to improve the “cure” rate obtained by surgery 
in resectable PDAC patients (Table 1).
The second question is: how do we build on current 
standards to push forward survival of advanced 
PDAC patients even further? In relation to this, is the 
question of if, and how, we can integrate promising 
molecularly targeted agents into current treatment 
paradigms. Many ongoing phase Ⅰ-Ⅱ trials (Tables 2 
and 3) are aimed at making the most of both worlds 
(polychemotherapy approaches and nab-Paclitaxel) 
and try to incorporate nab-Paclitaxel into PEFG- or 
FOLFIRINOX-like backbones, mostly by substituting 
nab-Paclitaxel for one of the components of the 
original regimen[89] (see also NCT01730222 and 
NCT02109341, Tables 2 and 3). An “add on” strategy 
is also the preferred design to try incorporating 
biological agents into first-line treatment (Tables 2 
and 3). Such a strategy, however, has many potential 
pitfalls in our opinion: (1) if we are to learn from 
past experience, twenty years of negative studies 
using the Gem vs Gem + an additional agent (either 
a second chemotherapy drug or a targeted agent) 
paradigm should have taught us that such an “add on 
to current standard” strategy does not pay off (nab-
Paclitaxel/Gem being the only notable exception)[24,38]; 
(2) while the combination of nab-Paclitaxel/Gem 
may still constitute a reasonable backbone for “add 
on” strategies, FOLFIRINOX-like regimens have 
substantial toxicity issues (so that most groups 
have adopted “modified” schedules), making it very 
unlikely that other agents may be simply added, 
without modifying the original regimen (and thereby 
potentially diminishing its efficacy); and (3) one of 
the most important clinical consequences of finally 
having “active” first-line regimens is that an increasing 
proportion of patients experience prolonged disease 
control, which enables them to receive a second or 
subsequent lines of therapy with clinical benefit. Thus, 
if the aim is to prolong disease control across multiple 
lines of treatment using all or most active agents 
upfront may actually turn out to be detrimental over 
the entire course of the disease. 
Although there is no easy solution to the challenge 
of identifying optimal development strategies in 
advanced PDAC, one possibility is to exploit different 
disease settings, as an alternative to the classical “all in 
first-line” or “at relapse” strategies, to test the activity 
of new agents. In this respect, data recently obtained 
in the maintenance setting, even with a relatively 
inactive (in first- or second-line) class of agents 
such as VEGF/VEGFR inhibitors[90-93], is extremely 
provocative. Indeed, these results raise the interesting 
hypothesis that targeting the VEGFR pathway, which 
may be of marginal relevance and insufficient to alter 
the natural history of the disease against a bulky 
and rapidly growing tumor, could still be effective 
against progression under conditions of maximum 
cytoreduction and chemotherapy-induced tumour 
damage As more patients achieve disease control at 
6 mo and as more active agents against pancreatic 
cancer become available, the maintenance setting may 
potentially achieve even more exciting results. Another 
disease setting that is currently relatively unexplored 
as a testing arena for new drugs is neoadjuvant 
treatment, which would also have the advantage of 
being able to truly (histologically) assess response and 
get access to post-treatment cancer tissue and tumor 
microenvironment, to look for drug effects on specific 
pathways/tissue components. 
Last, but not least, thanks to novel technologies 
and “omics”-based characterization efforts, the 
molecular classification of pancreatic cancer(s) is 
evolving, as in many other malignancies, towards the 
clusterization of individual cases in discrete subgroups, 
characterized by alterations in common pathways. 
Some of these “driver” alterations could already 
be exploited therapeutically, while some other will 
require more preclinical modeling efforts, in order to 
make them suitable therapeutic targets. In addition 
to yielding novel therapeutic targets, such efforts 
are expected to rapidly lead to the identification of 
potentially predictive biomarkers, which would help 
select populations of pancreatic cancer patients who 
would derive the most benefit from specific therapeutic 
approaches. While eagerly awaiting this “new wave” of 
biology-based improvements in pancreatic cancer care, 
we will continue to work together with our patients and 
look at the therapeutic options that have been made 
recently available with renewed hope.
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